AMYGDALA NEUROSCIENCES, INC.
Palo Alto, CA · Founded 2015 · CIK 0001640814 · Biotech · Private
Selective, reversible ALDH2 inhibitor small-molecule therapeutic for alcohol use disorder
- Grants
- $225K
- 1 award
- Sector median: 1
- Raised
- $7.0M
- 2 Form D · Nov 2019
- 82 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 21
- 5 granted · 16 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,449,990 | |
| Private capital raised | Form D · SEC | $5,594,783 | |
| Federal grant | Department of Health and Human Services · Phase I · Discovery next generation inhibitors of ALDH2 to reduce craving and alcohol consumption in alcohol use disorders | $224,500 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2491 | CELL DATA SCIENCES, INC. | — | — |
| 2492 | Cerevel Therapeutics | — | — |
| 2493 | BIOMARCK PHARMACEUTICALS, LTD | — | $8.0M |
| 2494 | AMYGDALA NEUROSCIENCES, INC. | — | $7.0M |
| 2495 | Cirrus Therapeutics, Inc. | — | $6.7M |
| 2496 | Semnur Pharmaceuticals, Inc. | — | $6.0M |
| 2497 | b3 bio, inc. | — | $5.7M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Ivan DiamondDirector · Executive Officer
- Howard JaffeDirector
- Louis LangeDirector
- William LeeDirector
- Adrienne MacMillanExecutive Officer
- Mack Mitchell, Jr.Director
- Peter StrumphDirector · Executive Officer
Patents
- ALDH-2 Inhibitor Compounds And Methods Of Usegranted
- ALDH-2 Inhibitor Compounds And Methods Of Useapplication
- ALDH-2 Inhibitor Compounds And Methods Of Usegranted
- ALDH-2 Inhibitor Compounds And Methods Of Usegranted
- Addiction Treatment Of An Alcohol-consuming Patient Populationapplication
- Combination Therapy For Nicotine Addictionapplication
- Combination Therapy For Preventing Addictionapplication
- Compounds For The Treatment Of Addictiongranted
- Compounds For The Treatment Of Addictiongranted
- ALDH-2 Inhibitor Compounds And Methods Of Useapplication
- ALDH-2 Inhibitor Compounds And Methods Of Useapplication
- Addiction Treatment Of An Alcohol-consuming Patient Populationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.